despit
induct
immunosuppress
use
aggress
mainten
immunosuppress
regimen
acut
allograft
reject
follow
lung
transplant
still
problem
import
diagnost
therapeut
challeng
well
caus
earli
graft
loss
mortal
acut
reject
also
initi
chronic
alloimmun
respons
airwaycentr
inflamm
predispos
bronchiol
obliteran
syndrom
bo
also
known
chronic
lung
allograft
dysfunct
clad
major
sourc
morbid
mortal
lung
transplant
cellular
respons
human
leukocyt
antigen
hla
allograft
tradit
consid
main
mechan
acut
reject
influenc
humor
immun
increasingli
recognis
sever
solid
organ
transplant
antibodymedi
reject
amr
wellaccept
distinct
clinic
entiti
lung
transplant
acut
cellular
reject
acr
defin
histopatholog
criteria
transbronchi
biopsi
less
use
amr
diagnosi
complic
challeng
measur
antibodi
direct
donor
hla
determin
signific
increas
awar
import
nonhla
antigen
cloud
issu
review
pathophysiolog
diagnosi
clinic
present
treatment
acr
amr
lung
transplant
discuss
futur
potenti
biomark
process
may
forward
understand
condit
acut
reject
pulmonari
allograft
remain
potenti
caus
acut
graft
failur
commonli
present
subacut
often
subtl
graft
dysfunct
argument
continu
regard
riskbenefit
schedul
surveil
lung
biopsi
program
indic
therapeut
intervent
time
focu
techniqu
improv
oper
characterist
surveil
clinic
mandat
procedur
well
kappa
score
report
histopathologist
brave
beat
distant
drum
herald
potenti
util
gene
transcript
analysi
technolog
supplant
current
gold
standard
theoret
appeal
valid
crucibl
real
time
clinic
practic
time
wise
continu
qualiti
control
measur
improv
safeti
procedur
adequaci
sampl
provid
histopathologist
expert
clinic
input
final
diagnos
therapi
accord
consensu
guidelin
statement
lung
transplant
potenti
acut
graft
dysfunct
failur
major
establish
risk
factor
develop
chronic
lung
allograft
dysfunct
clad
particularli
bronchiol
obliteran
syndrom
bo
earli
detect
treatment
acut
reject
thu
critic
import
lung
transplant
recipi
antibodi
mediat
reject
amr
may
occur
concurr
separ
acr
requir
addit
diagnost
therapeut
manoeuvr
cover
later
manuscript
registri
data
intern
societi
heart
lung
transplant
ishlt
show
third
patient
least
one
episod
treat
reject
first
year
transplant
furthermor
acut
reject
respons
death
among
adult
lung
transplant
recipi
first
day
period
month
posttranspl
acr
common
form
acut
lung
transplant
reject
like
diagnos
within
first
month
follow
lung
transplant
compar
larg
bodi
data
risk
factor
clad
recipi
immunolog
environment
factor
predict
acr
less
well
studi
report
risk
factor
acr
includ
degre
human
leukocyt
antigen
hla
mismatch
discrep
certain
locisuch
hladr
hlab
hlaa
greater
signific
geneticallydetermin
differ
innat
adapt
recipi
immunolog
respons
allograft
younger
age
also
associ
higher
rate
reject
first
year
transplant
whether
associ
confound
indic
transplant
underli
diseas
process
unclear
impact
induct
mainten
immunosuppress
incid
acr
studi
evid
ishlt
registri
data
suggest
protect
effect
receptor
antagonist
basiliximab
daclizumab
compar
induct
use
antagonist
alemtuzumab
howev
pauciti
randomis
trial
data
support
observ
systemat
review
could
find
differ
induct
agent
mainten
immunosuppress
tacrolimu
associ
lower
rate
bo
cyclosporin
evid
support
use
cyclosporin
acr
less
conclus
despit
registri
data
singl
random
trial
support
use
systemat
review
could
conclus
demonstr
benefit
lastli
infect
particularli
communityacquir
viral
infect
like
respiratori
syncyti
viru
rsv
coronaviru
rhinoviru
influenza
parainfluenza
virus
potenti
via
stimul
innat
immun
exposur
cryptic
antigen
epitheli
injuri
may
stimul
alloimmun
respons
precipit
acr
acr
respons
driven
lymphocyt
recognis
foreign
major
histocompat
complex
mhc
antigen
also
call
hla
allogen
tissu
function
mhc
bind
foreign
antigen
peptid
display
surfac
antigen
present
cell
apc
present
cell
mhc
gene
code
short
arm
chromosom
highli
polymorph
result
extrem
divers
individu
differ
mhc
individu
major
immunolog
barrier
transplant
mhc
molecul
act
antigen
permit
rapid
recognit
self
nonself
cellular
reject
allograft
two
distinct
pathway
allorecognit
implic
direct
pathway
donor
dendrit
cell
migrat
graft
secondari
lymphoid
tissu
passeng
leukocyt
present
mhc
directli
recipi
cell
indirect
pathway
recipi
dendrit
cell
process
present
alloantigen
deriv
die
donor
apc
cell
either
secondari
lymphoid
organ
allograft
figur
nonimmunolog
process
like
ischaemia
reperfus
injuri
pulmonari
infect
may
caus
nonspecif
activ
local
innat
immun
stimul
acut
reject
mechan
complet
elucid
recipi
tcell
activ
undergo
clonal
expans
differenti
alloreact
killer
cell
also
call
cytotox
lymphocyt
migrat
graft
dock
allograft
mhc
molecul
initi
tissu
destruct
effect
blockad
cell
activ
prolifer
requir
prevent
reject
advent
calcineurin
inhibitor
revolutionari
advanc
area
featur
may
mimic
mani
infecti
postinfecti
complic
affect
lung
transplant
recipi
short
breath
cough
without
sputum
product
even
lowgrad
fever
observ
acr
sign
symptom
reliabl
use
distinguish
opportunist
pulmonari
infect
increas
grade
reject
associ
sever
symptom
convers
mani
episod
acr
may
diagnos
routin
surveil
transbronchi
biopsi
earli
posttranspl
period
asymptomat
patient
physic
examin
may
normal
reveal
squeak
crackl
featur
pleural
effus
specif
laboratori
find
acr
increas
peripher
blood
eosinophil
count
preced
clinic
signific
acr
lung
heart
transplant
diagnost
accuraci
posit
predict
valu
find
modest
best
recent
review
peripher
blood
find
acr
suggest
differenti
count
use
guid
diagnosi
absolut
eosinophil
count
greater
cell
absolut
lymphocyt
greater
cell
rel
basophil
count
greater
favour
reject
neutrophil
count
greater
favour
infect
howev
diagnost
accuraci
algorithm
requir
formal
evalu
clinic
practic
spirometri
easili
perform
noninvas
safe
repeat
test
routin
perform
followup
visit
even
patient
home
screen
recipi
risk
reject
usual
spirometr
abnorm
acr
airflow
limit
reduc
forc
expiratori
volum
one
second
fev
declin
fev
stabl
baselin
persist
hour
gener
trigger
need
investig
util
spirometri
may
less
help
singl
lung
transplant
chang
may
confound
progress
diseas
nativ
lung
howev
stabl
spirometri
exclud
acr
specif
spirometri
also
low
airwaycentr
process
acut
infect
airway
anastomot
problem
caus
similar
reduct
fev
chest
xray
routin
obtain
investig
lung
transplant
recipi
new
respiratori
symptom
earli
posttranspl
period
recipi
acr
may
demonstr
bilater
pulmonari
infiltr
plain
radiographi
sensit
discrimin
valu
plain
radiograph
poor
highresolut
comput
tomographi
hrct
find
gener
also
nonspecif
howev
recent
studi
found
presenc
bilater
groundglass
opac
lower
lobe
predomin
associ
interlobular
septal
thicken
absenc
featur
fluid
overload
cardiomegali
consolid
atelectasi
posit
predict
valu
acut
reject
import
histolog
gold
standard
diagnosi
acr
clear
nonspecif
natur
poor
diagnost
accuraci
clinic
paramet
noninvas
investig
list
presumpt
diagnosi
acr
requir
intensif
immunosuppress
could
potenti
hazard
presenc
altern
diagnosi
particularli
undiagnos
opportunist
infect
need
make
confid
tissu
diagnosi
acr
reliabl
exclud
intrapulmonari
infect
thu
overemphasis
may
occur
simultan
bronchoscopi
allow
invas
sampl
histopatholog
determin
well
collect
bronchoalveolar
lavag
fluid
tissu
cytolog
microbiolog
analysi
usual
practic
biopsi
one
lung
heartlung
bilater
lung
recipi
case
radiograph
patchi
diseas
transbronchi
biopsi
direct
involv
area
absenc
radiolog
abnorm
diffus
diseas
transbronchi
biopsi
routin
obtain
lower
lobe
mani
centr
also
ipsilater
right
middl
lobe
lingula
depend
side
biopsi
wherea
upper
lobe
less
commonli
biopsi
geograph
distribut
reject
grade
amongst
lung
lobe
shown
similar
avoid
upper
lobe
biopsi
reduc
risk
iatrogen
pneumothorax
lung
reject
studi
group
lrsg
recommend
minimum
piec
evalu
wellexpand
alveolar
parenchyma
provid
adequ
sensit
diagnos
acr
studi
shown
amount
reliabl
obtain
perform
biopsi
specimen
result
low
complic
rate
complic
rate
lung
transplant
recipi
low
includ
order
frequenc
desatur
haemorrhag
ml
pneumothorax
postprocedur
pneumonia
arrhythmia
need
mechan
ventil
mortal
procedur
report
figur
h
e
h
p
h
l
g
c
l
h
l
l
r
k
f
c
r
h
e
demonstr
transbronchi
lung
biopsi
mononuclear
inflammatori
cell
infiltr
centr
around
small
vessel
capillari
andor
small
airway
lrsg
ishlt
develop
work
formul
standard
nomenclatur
diagnosi
lung
reject
last
revis
establish
diagnost
criteria
acr
object
grade
sever
tabl
perivascular
inflamm
term
agrad
evalu
presenc
extent
mononuclear
cell
invasioncompos
chiefli
cell
although
bcell
eosinophil
also
describ
around
blood
vessel
surround
submucos
interstitium
alveolar
wall
grade
rang
reject
sever
airway
inflamm
term
bgrade
reject
evalu
lymphocyt
respons
submucosa
bronchiol
may
extend
basement
membran
higher
grade
interpret
bgrade
reject
problemat
airway
tissu
often
repres
transbronchi
biopsi
specimen
airwaycentr
mononuclear
inflamm
specif
also
seen
episod
acut
infect
find
signific
airway
neutrophilia
necrosi
granuloma
viral
cytopath
effect
togeth
perivascular
peribronchiolar
inflamm
may
favour
infect
reject
although
import
rememb
two
process
mutual
exclus
occur
contemporan
gener
lrsg
advis
grade
aand
bgrade
reject
rigor
exclus
infect
process
confound
histolog
diagnosi
acr
includ
drug
toxic
aspir
ischaemiareperfus
injuri
amr
recurr
primari
diseas
sensit
transbronchi
lung
biopsi
diagnos
acr
highli
depend
experi
histopathologist
despit
attempt
standardis
histolog
interpret
acr
interobserv
agreement
modest
revis
attempt
improv
followup
studi
shown
increas
concord
promis
techniqu
studi
increas
diagnost
yield
acr
obtain
lung
tissu
cryobiopsi
cryobiopsi
rel
new
intervent
bronchoscop
techniqu
yield
larger
specimen
better
represent
airway
alveoli
vascular
structur
cryobiopsi
procedur
flexibl
cryoprob
deliv
compress
ga
tip
probe
freez
tissu
probe
tip
disadvantag
need
intub
theoret
concern
higher
risk
pneumothorax
haemorrhag
recent
studi
cryobiopsi
lung
transplant
recipi
howev
found
repres
specimen
less
crush
artefact
without
higher
rate
complic
compar
convent
biopsi
role
surveil
transbronchi
biopsi
asymptomat
lung
transplant
recipi
regular
interv
controversi
univers
practis
amongst
lung
transplant
centr
schedul
surveil
bronchoscopi
vari
gener
involv
monthli
biopsi
immedi
posttranspl
period
incid
acr
highest
continu
less
regular
interv
period
month
transplant
rational
surveil
high
incid
asymptomat
acr
observ
suboptim
diagnost
accuraci
noninvas
test
describ
prospect
cohort
studi
shown
incid
highgrad
perivascular
airway
inflamm
routin
surveil
biopsi
respect
howev
despit
find
evid
earli
detect
acr
subsequ
augment
immunosuppress
alter
outcom
lung
transplant
lack
small
studi
randomis
patient
either
surveil
bronchoscopi
clinicallyind
biopsi
find
differ
acut
reject
develop
clad
surviv
identif
object
repeat
specif
noninvas
test
could
replac
transbronchi
biopsywhich
discuss
imperfect
gold
standard
modest
interobserv
reliabilityfor
diagnosi
acr
remain
attract
elus
goal
furthermor
absenc
suitabl
biomark
current
practic
also
use
serum
drug
level
calcineurin
inhibitor
proxi
degre
immunosuppress
intens
shown
correl
lower
incid
acut
reject
latter
approach
obviou
drawback
least
pharmacokinet
pharmacogenet
variat
individu
futur
identif
biomark
indic
underli
state
immun
activ
andor
reject
would
much
better
guid
inform
ongo
immunosuppress
prescript
sever
potenti
biomark
current
evalu
exhal
nitric
oxid
feno
marker
underli
lung
inflamm
lung
transplant
recipi
well
studi
level
significantli
elev
compar
baselin
valu
patient
acr
especi
lymphocyt
airway
inflamm
specif
poor
pulmonari
infect
also
increas
feno
quantif
donorderiv
cell
free
dna
ddcfdna
allograft
circul
plasma
detect
nextgener
sequenc
excit
bloodbas
biomark
solid
organ
transplant
preliminari
work
suggest
increas
level
ddcfdna
associ
acut
chronic
reject
r
bgrade
inflamm
denot
revis
acr
acut
cellular
reject
correl
close
histopatholog
featur
acr
associ
declin
lung
function
howev
valid
studi
still
requir
optim
cutoff
valu
yet
determin
also
sever
direct
function
test
immun
function
commerci
avail
cylex
immun
cell
function
assay
immuknow
cylex
inc
columbia
md
usa
measur
atp
synthesi
activ
cell
exposur
stimul
phytohemagglutinin
measur
cellmedi
immun
sensit
acr
seem
low
alloreact
tcell
frequenc
assay
demonstr
increas
treg
prolifer
mix
lymphocyt
reaction
donor
antigen
acr
clinic
applic
limit
complex
assay
alloimmun
respons
lastli
transcriptom
signatur
acr
studi
microrna
mirna
small
noncod
rna
molecul
critic
control
posttranscript
regul
gene
express
sever
studi
implic
involv
renal
heart
transplant
reject
small
studi
lung
transplant
recipi
identifi
distinct
mirna
signatur
airway
epithelium
distinguish
patient
acr
without
reject
even
promis
mirna
profil
detect
cardiac
acr
found
peripher
blood
potenti
mirna
bloodbas
marker
acr
excit
futur
field
studi
treatment
decis
depend
institut
practic
histolog
grade
reject
whilst
consensu
treat
higher
grade
acut
perivascular
reject
symptomat
grade
manag
minim
mild
reject
asymptomat
grade
isol
bgrade
reject
controversi
centr
elect
treat
latter
situat
rather
repeat
biopsi
week
time
howev
consid
minim
reject
shown
associ
increas
risk
clad
compar
higher
grade
reject
lymphocyt
bronchiol
bgrade
reject
also
shown
independ
associ
increas
risk
clad
death
type
grade
acr
probabl
strongli
consid
treatment
especi
patient
clinic
syndrom
suggest
reject
special
consider
may
asymptomat
patient
minim
reject
bgrade
reject
detect
surveil
biopsi
augment
immunosuppress
may
consider
jeopardis
treatment
current
seriou
opportunist
viral
fungal
infectionin
situat
defer
treatment
rebiopsi
may
safer
strategi
cornerston
treatment
acr
steroid
puls
howev
studi
data
guid
dose
durat
therapi
centr
advoc
pulseddos
methylprednisolon
day
transit
taper
oral
steroid
wean
clinician
use
oral
prednisolon
mgkg
milder
grade
reject
although
evid
practic
lack
centr
perform
surveil
bronchoscopi
also
perform
followup
bronchoscopi
week
episod
acr
practic
support
find
signific
rate
persist
acr
often
clinic
occult
manag
persist
refractori
acr
well
establish
failur
respond
treatment
acr
trigger
investig
concomit
amr
togeth
repeat
steroid
puls
chang
therapi
case
persist
acr
may
includ
switch
tacrolimu
cyclosporinebas
regimen
addit
mammalian
target
rapamycin
mtor
inhibitor
everolimu
potenti
treatment
consid
avail
includ
alemtuzumab
antibodi
peptid
present
surfac
matur
lymphocyt
caus
antibodydepend
lysi
lymphocyt
extracorpor
photophoresi
ecp
ecp
thought
reduc
immun
respons
transplant
recipi
stimul
expand
number
peripher
regulatori
tcell
shown
stabilis
recurr
acr
amelior
lung
function
declin
clad
discuss
acut
reject
post
lung
transplant
ltx
cellular
driven
immun
respons
histor
consid
main
mechan
acut
lung
allograft
reject
past
decad
howev
role
play
antibodi
acut
lung
allograft
well
clad
stimul
grow
interest
amr
evolv
hypothet
controversi
concept
import
diagnost
consider
patient
acut
allograft
dysfunct
wellrecognis
clinic
entiti
post
lung
transplant
much
initi
understand
pulmonari
amr
extrapol
renal
heart
transplant
literatur
amr
recognis
time
one
biggest
difficulti
face
clinician
reach
diagnosi
amr
choos
suitabl
manag
strategi
lack
standardis
data
avail
differ
studi
use
variou
criteria
diagnosi
signific
develop
public
first
consensu
document
pulmonari
amr
ishlt
consensu
document
provid
much
need
standardis
criteria
use
defin
amr
facilit
univers
interpret
futur
research
gener
accept
activ
document
ongo
research
well
increas
number
recognis
pulmonari
amr
diagnos
gener
inform
help
us
understand
pathophysiolog
pulmonari
amr
address
numer
question
yet
remain
unansw
section
address
pathophysiolog
diagnosi
clinic
present
classif
treatment
amr
explor
diagnost
manag
challeng
polymorph
natur
hla
antigen
provid
differ
endogen
antigen
present
cell
subsequ
activ
b
cell
plasma
cell
produc
dsa
target
graft
dsa
may
form
prior
transplant
patient
previous
sensit
follow
exposur
allogen
tissu
via
previou
pregnanc
blood
transfus
transplant
may
also
develop
de
novo
post
ltx
rate
detect
dsa
singl
antigen
bead
sab
test
variou
studi
rang
patient
within
year
post
lung
transplant
detect
posttranspl
serum
associ
significantli
increas
risk
amr
clad
signific
pretranspl
dsa
well
establish
kidney
heart
transplant
lung
associ
acut
chronic
effect
lung
allograft
includ
refractori
acut
reject
lymphocyt
bronchiol
amr
clad
preform
dsa
also
report
promot
de
novo
dsa
develop
earli
transplant
impact
patient
surviv
graft
injuri
result
dsa
occur
via
complementdepend
complementindepend
mechan
initi
activ
step
format
antigenantibodi
complex
result
amplifi
immun
respons
numer
downstream
effect
complementdepend
pathway
otherwis
known
classic
pathway
antibodi
bind
correspond
hlaantigen
airway
epithelium
result
antigenantibodi
complex
activ
complement
cascad
howev
complement
alway
necessari
antibodi
caus
graft
damag
abl
directli
act
inflammatori
cell
macrophag
natur
killer
cell
neutrophil
via
interact
fc
receptor
portion
antibodi
induc
proinflammatori
cytokin
product
microangiopathi
patient
dsa
present
serum
exhibit
featur
amr
could
due
variabl
pathogen
igg
subclass
differ
igg
variabl
affin
bind
fc
receptor
usual
consid
noncompl
bind
bind
complement
former
strongest
affin
fc
receptor
howev
high
antigen
epitop
level
increas
complement
concentr
igg
subclass
abil
activ
complement
may
therefor
case
wolf
sheep
cloth
dsa
may
previous
consid
rel
benign
becom
pathogen
depend
chang
within
immunolog
environ
inflammatori
respons
certain
trigger
dsa
hla
tradit
consid
respons
amr
lung
allograft
injuri
howev
patient
meet
criteria
amr
evid
hladsa
grow
evid
support
role
nonhla
dsa
tissu
selfantigen
sag
direct
toward
epitheli
antigen
kalpha
tubulin
collagen
v
colv
may
account
unmeasur
hladsa
patient
amr
similarli
patient
dsa
clearli
present
yet
exhibit
manifest
amr
suggest
altern
factor
may
influenc
suscept
risk
reject
presenc
antibodi
bind
graft
signific
work
done
bharat
colleagu
sag
work
demonstr
patient
undergo
lung
transplant
preexist
antibodi
colv
strongli
predispos
patient
primari
graft
dysfunct
pgd
develop
de
novo
alloimmun
clad
group
introduc
concept
two
hit
hypothesi
develop
sag
initi
hit
involv
initi
lung
injuri
result
trigger
infect
commun
acquir
respiratori
virus
carv
gastrooesophag
reflux
diseas
gord
ischaemiareperfus
injuri
even
presenc
hladsa
result
local
inflammatori
respons
expos
sag
colv
stimul
upregul
selfreact
lymphocyt
nonhla
antibodi
product
second
hit
result
downregul
regulatori
cell
treg
loss
inhibit
selfreact
lymphocyt
sag
would
usual
induc
cell
toler
sag
ultim
lead
sag
autoimmun
bharat
sag
may
signific
contribut
factor
ongo
clad
patient
clear
dsa
post
amr
treatment
use
commerci
avail
kit
measur
sag
studi
hachem
et
al
previous
shown
ltx
recipi
preexist
hladsa
develop
de
novo
sag
within
three
year
ltx
strongli
predispos
develop
clad
howev
amr
treatment
effect
reduc
increas
risk
clad
sag
clear
well
hladsa
patient
clear
hladsa
persist
sag
share
equal
risk
clad
hladsa
sag
ongo
inflamm
patient
post
ltx
recipi
endstag
lung
diseas
provid
ideal
environ
hypothesi
particularli
patient
cystic
fibrosi
cf
ongo
infect
patient
idiopath
pulmonari
fibrosi
ipf
ongo
inflamm
studi
demonstr
higher
preval
sag
pretranspl
patient
cf
ipf
compar
patient
condit
copd
wherea
studi
shown
lead
expans
autoreact
lymphocyt
individu
diseas
highest
preval
sag
preltx
compar
patient
diseas
copd
antitrypsin
defici
futur
research
doubt
help
clarifi
associ
pathophysiolog
amr
clad
howev
data
need
prove
link
phenomena
transbronchi
biopsi
safe
perform
essenti
compon
diagnost
algorithm
patient
present
drop
lung
function
baselin
consid
gold
standard
diagnosi
acr
howev
appear
capillari
injuri
neutrophil
margin
neutrophil
capillar
arter
consid
pathologist
suggest
amr
help
clinician
make
confid
diagnosi
address
diagnost
criteria
current
mandat
ishlt
morpholog
featur
suggest
amr
pathognomon
occur
diseas
process
involv
lung
infect
organis
pneumonia
diffus
alveolar
damag
dad
secondari
caus
well
acr
grade
case
dsa
absenc
featur
exclud
amr
clinic
context
need
taken
consider
contempl
diagnosi
effort
need
made
exclud
caus
infect
although
two
may
coexist
although
two
may
coexist
identif
stain
biopsi
sampl
surrog
marker
amr
due
activ
complement
cascad
controversi
role
diagnosi
pulmonari
amr
may
overestim
rare
seen
patient
diagnosi
pulmonari
amr
base
criteria
poor
interpathologist
agreement
come
recognis
posit
stain
transbronchi
biopsi
notabl
specif
pulmonari
amr
found
process
associ
complement
activ
reperfus
injuri
infect
studi
shown
littl
correl
posit
stain
presenc
dsa
clinic
present
pulmonari
amr
variabl
depend
time
posttranspl
hyperacut
reject
occur
soon
vascular
anastomosi
complet
recipi
immun
cell
come
contact
donor
recipi
endotheli
cell
preform
antibodi
alreadi
present
time
transplant
sole
respons
devast
effect
type
reject
graft
failur
occur
within
minut
hour
usual
fatal
result
acut
sever
refractori
hypoxaemia
respiratori
failur
diffus
pulmonari
infiltr
seen
radiolog
examin
histopatholog
reveal
neutrophil
margin
vascul
fibrinoid
necrosi
vascular
thrombosi
pulmonari
infarct
introduct
highli
sensit
assay
detect
dsa
incid
hyperacut
reject
significantli
reduc
howev
antibodi
respons
donor
hla
antigen
well
control
current
convent
immunesuppress
therefor
acut
amr
occur
time
transplant
either
pretranspl
hla
de
novo
hla
nonhla
dsa
autoantibodi
colv
respons
mediat
allograft
injuri
chronic
indol
form
amr
thought
contribut
develop
clad
due
bo
even
rclad
insuffici
data
confirm
associ
high
index
suspicion
necessari
consid
pulmonari
amr
possibl
diagnosi
clinic
present
often
nonspecif
patient
may
often
present
asymptomat
drop
lung
function
nonspecif
symptom
cough
dyspnoea
fever
lethargi
rapidli
progress
profound
dyspnoea
progress
respiratori
failur
requir
increas
oxygen
supplement
mechan
ventil
case
ecmo
attempt
buy
time
rescu
therapi
work
diagnosi
amr
challeng
high
level
clinic
vigil
paramount
current
classif
system
requir
evid
lung
allograft
dysfunct
histolog
chang
consist
amr
posit
stain
presenc
dsa
multidisciplinari
approach
address
need
consid
clinic
present
well
immunolog
patholog
inform
obtain
diagnost
process
therefor
recommend
includ
measur
allograft
function
ii
histopatholog
assess
includ
stain
iii
evalu
presenc
dsa
diagnosi
amr
usual
made
process
investig
patient
drop
lung
function
greater
baselin
usual
involv
radiolog
investig
includ
computeris
tomographi
scan
chest
nasopharyng
swab
respiratori
virus
bronchoscopi
bronchoalveolar
lavag
look
infecti
aetiolog
well
airway
abnorm
may
contribut
loss
graft
function
safe
transbronchi
biopsi
also
undertaken
gold
standard
diagnos
acr
allow
assess
featur
consist
amr
includ
stain
figur
serolog
detect
dsa
use
sab
also
request
identif
dsa
evolv
time
provis
rather
crude
measur
presenc
dsa
mix
donor
lymphocyt
recipi
serum
find
recipi
cell
lysi
indic
presenc
dsa
call
complementdepend
cytotox
cdc
assay
modifi
version
test
reli
use
panel
hlaphenotyp
cell
express
result
percentag
cell
panel
give
posit
result
panel
reactiv
antibodi
pra
percentag
higher
percentag
pra
indic
higher
probabl
posit
crossmatch
vice
versa
develop
solid
phase
sab
technolog
allow
sensit
accur
identif
dsa
assay
involv
incub
patient
serum
bead
coat
two
fluorochrom
result
uniqu
signal
bead
specif
hla
molecul
produc
recombin
technolog
also
attach
bead
recipi
serum
incub
bead
hlaantibodi
present
react
bead
express
correspond
antigen
molecul
bead
wash
fluorolabel
antihuman
igg
antibodi
provid
mean
fluoresc
intens
mfi
repres
amount
fluorolabel
antiigg
complex
antihla
antibodi
mfi
accur
quantit
measur
amount
antibodi
concentr
requir
measur
antibodi
titr
given
perhap
surpris
ongo
controversi
regard
cut
level
mfi
consid
clinic
signific
posit
result
wherea
titr
inform
accur
random
arbitrari
select
mfi
threshold
determin
posit
sab
result
led
conflict
report
clinic
signific
dsa
relationship
clinic
outcom
post
transplant
studi
use
low
mfi
threshold
show
neg
effect
transplant
outcom
preexist
dsa
wherea
studi
chosen
slightli
higher
mfi
show
associ
increas
amr
risk
follow
lung
transplant
notabl
studi
report
lack
effect
dsa
mfi
valu
clearli
demonstr
import
select
mfi
threshold
valu
identifi
antihla
antibodi
mfi
threshold
may
explain
suggest
differ
pretranspl
dsa
class
ii
hla
associ
increas
risk
bo
decreas
surviv
suggest
studi
conduct
brugier
et
al
show
dsa
class
ii
hla
class
associ
increas
risk
bo
decreas
surviv
though
signific
differ
mfi
valu
anticlass
anticlass
ii
dsa
preclud
definit
assess
differ
biolog
impact
antibodi
class
class
ii
hla
longitudin
variabl
mfi
level
particular
antibodi
also
seen
thought
due
deposit
antibodi
graft
lead
level
circul
call
spong
effect
describ
girnita
colleagu
note
detect
dsa
serum
remov
graft
suspect
amr
also
unclear
whether
dsa
hla
locu
dsa
mfi
would
clinic
outcom
studi
shown
hla
class
ii
antibodi
may
signific
hla
class
antibodi
patient
develop
class
ii
dsa
persist
dsa
despit
antibodydeplet
therapi
wors
long
term
outcom
transplant
bind
assay
one
lambda
inc
canoga
park
california
usa
develop
attempt
determin
patient
detect
dsa
higher
risk
graft
injuri
base
presenc
complement
fix
dsa
much
inform
recogn
bind
physiolog
complement
activ
howev
clinic
util
demonstr
renal
heart
lung
transplant
complement
alway
requir
caus
antibodi
mediat
graft
injuri
sinc
dsa
abil
induc
damag
via
noncompl
depend
pathway
signific
limit
use
bind
predict
likelihood
antibodi
bind
complement
result
allograft
damag
amr
classifi
clinic
subclin
amr
clinic
amr
indic
allograft
dysfunct
wherea
subclin
amr
lung
function
normal
clinic
amr
subclassifi
definit
probabl
possibl
amr
need
allograft
dysfunct
consid
clinic
amr
addit
criteria
consid
includ
exclus
caus
histolog
chang
consist
amr
presenc
stain
biopsi
presenc
dsa
criteria
met
definit
amr
criteria
met
classifi
probabl
amr
wherea
presenc
criteria
classifi
possibl
amr
subclin
amr
also
subclassifi
definit
probabl
possibl
howev
allograft
dysfunct
definit
subclin
amr
histolog
consist
amr
posit
stain
presenc
dsa
probabl
subclin
amr
consist
presenc
criteria
possibl
amr
criteria
tabl
figur
hyperacut
reject
occur
periop
acut
reject
discret
clinicallysymptomat
episod
chronic
reject
may
manifest
persist
allograft
dysfunct
result
cumul
ongo
patholog
event
rate
hyperacut
reject
significantli
reduc
result
introduct
highli
sensit
assay
use
time
crossmatch
manag
amr
pose
ongo
dilemma
physician
care
patient
diagnosi
amr
made
sinc
clear
evid
determin
best
manag
option
amr
post
lung
transplant
randomis
control
head
head
studi
current
data
support
variou
treatment
modal
aris
retrospect
studi
case
report
case
seri
current
treatment
strategi
aim
deplet
modul
product
circul
dsa
attempt
arrest
graft
dysfunct
yet
clear
guidelin
consensu
manag
amr
post
lung
transplant
current
treatment
regimen
base
employ
solid
organ
transplant
includ
use
plasmapheresi
pp
intraven
human
immunoglobulin
ivig
rituximab
bortezomib
result
suboptim
pp
remov
antibodi
circul
report
amelior
lung
function
studi
ivig
caus
bcell
apoptosi
reduc
bcell
number
block
bind
donor
reactiv
antibodi
may
inhibit
complement
activ
rituximab
chimer
humanmurin
monoclon
antibodi
direct
molecul
found
matur
b
cell
prob
cell
plasma
cell
therefor
lead
elimin
peripher
b
cell
circul
effect
matur
plasma
cell
b
cell
lymphoid
tissu
bortezomib
proteasom
inhibitor
reduc
dsa
deplet
plasma
cell
caus
plasma
cell
apoptosi
clinic
use
support
within
renal
lung
transplant
literatur
effect
use
treat
amr
refractori
treatment
administr
bortezomib
subcutan
associ
less
side
effect
leucopoenia
neutropenia
thrombocytopenia
peripher
neuropathi
monoclon
antibodi
use
salvag
treatment
amr
includ
eculizumab
alemtuzumab
eculizumab
monoclon
antibodi
block
termin
complement
activ
alemtuzumab
monoclon
antibodi
bind
protein
present
surfac
matur
lymphocyt
treat
pulmonari
amr
may
stabilis
progress
improv
complet
respons
treatment
defin
return
baselin
function
abolit
dsa
revers
patholog
chang
partial
respons
improv
lung
function
paramet
return
baselin
stabilis
clinic
deterior
respons
defin
ongo
clinic
deterior
continu
patholog
journal
thorac
diseas
right
reserv
j
thorac
di
jtdamegroupscom
lung
transplant
uniqu
solid
organ
open
environ
undergo
continu
stimulu
infecti
noninfecti
stimuli
may
play
part
upregul
immun
system
therefor
higher
immun
suppress
necessari
longterm
surviv
remain
disappoint
clad
main
caus
death
current
immunosuppress
strategi
target
tcell
respons
seem
control
clad
may
suggest
altern
pathway
mechan
caus
ongo
graft
damag
amr
taken
centr
stage
recent
possibl
import
mediat
chronic
allograft
injuri
improv
knowledg
mechan
injuri
may
abl
identifi
target
treatment
enabl
us
gain
good
control
overal
improv
patient
surviv
post
transplant
